Manage Your Liver
Q:

I was recently diagnosed with NASH, I was told by my gastroenterologist that there is no available treatment. What can I do?

A:

Currently, there is no approved treatment for NASH. [1] As the underlying cause for the transition from simple fat buildup in the liver to NASH remain unknown, conventional medical therapies for NASH have not yet been proven to be effective. 

The recommendations medical professionals often give to people with NASH are to follow a healthy diet and do exercise. [2] Those who are overweight or obese are advised to lose weight, but this can be difficult and not every individual finds these interventions effective. 

There are things NASH patients can do other than losing weight. Apart from lifestyle changes, NASH patients should also focus on protecting their liver, reducing inflammation in the liver cells and preventing progression of the disease. In the long run, this can help to reduce the risk of cirrhosis and liver cancer.

A clinical study on PubMed suggests that YHK, an alternative therapy from Japan, has an inhibitory effect on the development of NASH; and its anti-inflammatory effect can effectively stop inflammation in the liver. [3] Other research papers also demonstrate that YHK has anti-fibrotic properties which prevent further damage to the liver such as fibrosis or cirrhosis. [4][5]

Stopping the progression of NASH is possible. But it will require putting in great effort to leading a healthy lifestyle and reducing fat and inflammation in the liver with the help of the above mentioned nutraceutical. Avoiding the use of alcohol and unnecessary medications can also decrease the risk of liver damage.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us